

TYSABRI (NATALIZUMAB) [PREFERRED] PRIOR AUTHORIZATION FORM

(form effective 1/3/2022)



Fax to PerformRxSM at **1-855-851-4058**, or to speak to a representative call **1-888-674-8720**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	Total # pages:	Name of office contact:
Contact's phone number:		LTC facility contact/phone:	

PATIENT INFORMATION			
Patient name:	Patient ID #:	DOB:	
Street address:	Apt. #:	City/state/zip:	

PRESCRIBER INFORMATION			
Prescriber name:	Specialty:		
State license #:	NPI:	MA Provider ID #	
Street address:	Suite #:	City/state/zip:	
Phone:	Fax:		

CLINICAL INFORMATION			
Medication requested: Tysabri (natalizumab) 300 mg/15 ml	Quantity:	vials	Refills:
Directions: <input type="checkbox"/> 300 mg SQ every 4 weeks <input type="checkbox"/> other: _____			Dx code (required):
Diagnosis: <input type="checkbox"/> relapsing multiple sclerosis – <i>Submit documentation of diagnosis and disease pattern.</i> <input type="checkbox"/> moderately to severely active Crohn's disease with inflammation – <i>Submit documentation of diagnosis and disease severity.</i> <input type="checkbox"/> other: _____ – <i>Submit documentation supporting the use of Tysabri for the patient's condition.</i>			

PHARMACY INFORMATION (Prescriber to identify the pharmacy that is to dispense the medication, if applicable):	
Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:	
Pharmacy Phone #:	Pharmacy Fax #:
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.	

HCPCS (HEALTHCARE COMMON PROCEDURE CODING SYSTEM) INFORMATION (if applicable):			
Treatment setting: <input type="checkbox"/> Infusion Center <input type="checkbox"/> Home <input type="checkbox"/> Provider's Office <input type="checkbox"/> Hospital Outpatient Facility			
Facility name:	Facility NPI:		
J-code:	Number of units:	Date of service (MM/DD/YYYY):	

INITIAL REQUESTS	
1. Is Tysabri (natalizumab) being prescribed by or in consultation with an appropriate specialist?	<input type="checkbox"/> Yes, list specialty: _____ <input type="checkbox"/> No
2. Is patient receiving chronic immunosuppressant or immunomodulator therapy?	<input type="checkbox"/> Yes, list medications: _____ <input type="checkbox"/> No
3. For the treatment of Crohn's disease, does at least one of the following apply to the patient?	<input type="checkbox"/> moderate to severe Crohn's disease and one of the following: <input type="checkbox"/> failed to achieve remission with or has a contraindication or intolerance to an induction course of corticosteroids <input type="checkbox"/> failed to maintain remission or has a contraindication or intolerance to immunomodulators <input type="checkbox"/> has one or more high-risk or poor prognostic features <input type="checkbox"/> has achieved remission with the requested medication and will be using the requested medication as maintenance therapy to maintain remission
4. For the treatment of Crohn's disease, select all that apply to the patient.	<input type="checkbox"/> history of trial and failure of at least one tumor necrosis factor (TNF) inhibitor OR contraindication or intolerance to TNF inhibitors; list medications tried OR provide explanation for contraindication/intolerance: _____ <input type="checkbox"/> history of therapeutic failure, contraindication, or intolerance to ustekinumab (Stelara) <input type="checkbox"/> history of therapeutic failure, contraindication, or intolerance to vedolizumab (Entyvio) <input type="checkbox"/> current history (within the past 90 days) of being prescribed Tysabri

RENEWAL REQUESTS	
1. For the treatment of multiple sclerosis, did the patient experience disease improvement or stabilization since starting Tysabri? <input type="checkbox"/> Yes <input type="checkbox"/> No	<i>Submit documentation of response to therapy.</i>
2. For the treatment of Crohn's disease, select all that apply to the patient.	<input type="checkbox"/> experienced therapeutic benefit within 3 months of starting therapy <input type="checkbox"/> was able to discontinue concomitant corticosteroid use within 6 months of starting therapy <input type="checkbox"/> did not require additional steroid use for more than 3 months in a calendar year

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION	
Prescriber signature:	Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.

Coverage by AmeriHealth First.

CHCPA_211717156-16